Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Recent studies have led to important insights regarding the role of viruses in asthma pathogenesis and exacerbations, as well as mediating factors involved in these processes.
Use of prophylactic antimicrobial therapy was not associated with a reduction in mortality or transfer to critical care compared with patients managed with supportive care only.
A new cystic fibrosis transmembrane conductance regulator modulator treatment has been approved by the FDA for use in patients aged 12 years and older.
Adults with cardiac arrest have better outcomes with continuous compressions with asynchronous ventilations or compression-to-ventilation ratios of 30:2.
